Cancer detection, treatments for Alzheimer's disease, cell enrichment, and more...
Pharmaceutical research and bio-technology are long term investments that are not traditionally associated with small entrepreneurs. The growth of Yokneam's Startup Village ecosystem attracted high-tech incubators and other sources of funding for Yokneam's budding pharma and bio-tech industry.
BioCEP develops, manufactures and sells cutting-edge technologies for cell isolation, worldwide. Its patented Cell Enrichment Process is incorporated in the CEPir (Cell Enrichment Process for Isolation of Rare Cells) cell isolation device enabling effective immunomagnetic cell isolation for R&D. The CEPir isolates rare cells at high purity and recovery rates offering an alternative to inferior traditional solutions.
The diagnosis of Parkinson's is mainly based on patients' medical history and clinical examination. In some cases Parkinson's disease can be difficult to diagnose with early signs and symptoms being dismissed as the effects of normal aging.
BioShai is developing PDx, a simple blood test for the early diagnosis of Parkinson’s disease. The blood test can be combined with other clinical data to provide a more complete diagnosis to help physicians decide on the best course of treatment.
PDx is based on the measurement of the level of expression of a set of genes. Gene expression is a dynamic process affected by stress, diet, and health leading to dramatic changes in the amount of messenger RNA molecules and protein in the human body over the course of our lives.
Expected to be on the market in 2017.
EpiTech is developing a revolutionized treatment for Dry Eye Syndrome.
GlaucoPharm is developing new therapeutic strategy for glaucoma – a uridine diphosphate (UDP) derivative that is an agonist of the P2Y6 receptor. TG-46 is of a different class from the drug classes currently used for the treatment of glaucoma (e.g. prostaglandin derivatives, beta-blockers). It is also a different class from those who are currently being investigated by pharmaceutical companies (e.g. Rho Kinase inhibitors).
Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of blindness in the world. Estimates put the total number of suspected cases of glaucoma at over 60 million worldwide.
For the past decade, Bara Herbs has been the leader of the future herbal medicine, through means of research and development, production, marketing and the setting up of a knowhow center for professionals. Bara's herbal products are well known for their therapeutic creativity and the highest quality of raw materials. The company specializes in the extraction and processing of more than 700 quality medicinal herbs from Israel and around the world.
The development of Bara's herbal products is based on extensive clinical experience, scientific research collaborations and most innovative production technologies – all of which guarantee the purest, whole extraction of each herb, upon its full spectrum of bioavailable constituents. Bara's herbal-based products are easy to integrate into the daily routine as they are available in various forms including tinctures, capsules, tablets, teas, syrups, ointments and oils.
NanoSpun develops and produces smart fibrous mats and surfaces which significantly improve biological processes. NanoSpun utilizes its proprietary nanotechnology, impressively controlled over the fiber properties and unique embodiment capabilities, to encapsulate designated active microorganisms within its fibrous permeable structures.
NanoSpun solution offers fundamental advantages over other competing technologies and its resulting products demonstrate efficient, cost-effective and easy to operate solutions which represent leapfrog advancement for humankind and sustainable environment.
RayFund is a mass participation fundraising platform for small entrepreneurs to enable them to raise capital for the long term investments required for pharmaceutical research and bio-technology. Our goal is to take market control out of the hands of giant companies who acquire patents and prevent others from competing with them in the market, thereby raising prices in medication instead of benefiting patients.